menu
    • menu

    Company profile for Synedgen

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Synedgen is a biotechnology company using glycochemistry to develop drugs that enhance and mimic the innate immune system. The company’s lead development candidate is SYGN305 for gastrointestinal mucositis, where a large unmet need exists to prevent intestinal radiation injury, the single most important dose-limiting factor in cancer radiotherapy. Synedgen’s glycochemistry platform has already generated five FDA 510(k)-cle...
    Synedgen is a biotechnology company using glycochemistry to develop drugs that enhance and mimic the innate immune system. The company’s lead development candidate is SYGN305 for gastrointestinal mucositis, where a large unmet need exists to prevent intestinal radiation injury, the single most important dose-limiting factor in cancer radiotherapy. Synedgen’s glycochemistry platform has already generated five FDA 510(k)-cleared therapeutics, one OTC drug, one veterinary indexed drug, and an out-licensed Phase 2 program, to Synspira, for the potential treatment of pulmonary complications of cystic fibrosis.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    SynedgenUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1420 N. Claremont Blvd., Suite 105 D Claremont, CA 91711
    Telephone
    Telephone
    (909) 447-6858
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.synedgen.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Synedgen Names Dr. Laura Saward CEO, Dr. Gregory CMO
    Synedgen Names Dr. Laura Saward CEO, Dr. Gregory CMO

    02 Jul 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250702204930/en/Synedgen-Promotes-Dr.-Laura-Saward-to-Chief-Executive-Officer-and-Appoints-Dr.-Kenton-Gregory-to-Chief-Medical-Officer

    BUSINESSWIRE
    02 Jul 2025
    Share Share
    Synedgen Announces Appoint of Dr. Laura as Chief Scientific Officer
    Synedgen Announces Appoint of Dr. Laura as Chief Scientific Officer

    10 Feb 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250210402492/en

    BUSINESSWIRE
    10 Feb 2025
    Share Share
    Synedgen Announces 2.2M Award for MIIST305 Radiation Countermeasure
    Synedgen Announces 2.2M Award for MIIST305 Radiation Countermeasure

    31 Oct 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241031125098/en

    BUSINESSWIRE
    31 Oct 2024
    Share Share
    Synedgen Receives BARDA Contract To Develop MIIST305
    Synedgen Receives BARDA Contract To Develop MIIST305

    15 Oct 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241015407037/en

    BUSINESSWIRE
    15 Oct 2024
    Share Share
    Synedgen Adds Dr. Hal J. Oien to its Board of Directors
    Synedgen Adds Dr. Hal J. Oien to its Board of Directors

    24 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240924446637/en

    BUSINESSWIRE
    24 Sep 2024
    Share Share
    Synedgen Completes IND-Enabling Studies for MIIST305 Programs
    Synedgen Completes IND-Enabling Studies for MIIST305 Programs

    25 Apr 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240425733873/en

    BUSINESSWIRE
    25 Apr 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search